Toddaculin

Research use only, not for human use.

Toddaculine may be beneficial for the prevention and treatment of osteoporosis, it can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1/2, and p38 MAPK signaling pathways.

Toddaculine may be beneficial for the prevention and treatment of osteoporosis, it can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1/2, and p38 MAPK signaling pathways, but can induce differentiation and mineralization of osteoblasts by regulating differentiation factors. Toddaculine also may serve as a pharmacological prototype for the development of novel anti-leukemic agents, it displays a dual effect as a cell differentiating agent and apoptosis inducer in U-937 cells.

Toddaculin (5-250 μM; 24-72 h) shows anti-proliferative activity in U-937 cells, with an IC50 of 51.38 μM.Toddaculin (25-250 μM; 24-48 h) induces partial differentiation in U-937 leukemic cells.

——

——

Others

Other Targets

Others

——

——

4335-12-0

274.3

C16H18O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (182.28 mM)

CC(C)=CCc(c(OC)cc(O1)c2C=CC1=O)c2OC

——

(-20℃)

With Ice Pack

≥ 2 years